Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Health Yuan inhalation preparation is selected into the new version of COPD guidelines
Published Time：
2021-03-15
Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (2021 Revised Edition) (hereinafter referred to as the "New Guidelines") New Guidelines were officially released recently. HealthGen Pharmaceutical Group Co., Ltd. (hereinafter referred to as "HealthGen")'s Lishutong (Salbutamol Hydrochloride Inhalation Solution) as the first and only domestically approved short-acting β 2 receptor agonist to be recommended for first-line treatment, also marks the official entry of China's independently developed high-standard inhalation preparations into market competition.
Data shows that the number of COPD patients in China has approached 100 million, becoming a common chronic disease on par with hypertension and diabetes, posing a huge challenge to China's public health and medical system. Inhalation preparations allow drugs to act directly on the target organ, and because of their rapid onset of action and fewer systemic adverse reactions, they are recommended by the new guidelines as the preferred treatment method for COPD. Currently, the vast majority of the Chinese market share has long been occupied by a small number of multinational pharmaceutical companies from Europe, America, and Japan. In recent years, under the leadership of Chairman Zhu Baoguo, HealthGen has actively responded to the national call, actively deploying respiratory drugs, and focusing on breakthroughs in the high-tech barriers of inhalation preparation research and development and production, taking the lead in breaking the monopoly of multinational pharmaceutical companies in the domestic market. The competitive landscape formed by these high-standard Chinese preparations entering the market is conducive to further reducing the medical burden and provides a new choice for a large number of COPD patients.
HealthGen's Lishutong (Salbutamol Hydrochloride Inhalation Solution) is the first and only domestically approved short-acting β 2 receptor agonist, and was included in the National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog (2020) (hereinafter referred to as the "National Medical Insurance Catalog") issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security in 2020, solving the threshold for drug access. This recommendation in the new guidelines means that Lishutong has gained recognition on the clinical front line, and also solves the problem of rational clinical drug use, solving the "last mile" problem.
Currently, HealthGen is in a leading position in China in terms of both R&D investment and R&D pipeline. HealthGen's already marketed products, such as Wushu (Budesonide Suspension for Inhalation), Shutanlin (Compound Ipratropium Bromide Solution for Inhalation), Liwuan (Ipratropium Bromide Solution for Inhalation), and the R&D product Indacaterol Dry Powder, etc., have also been recommended in the new guidelines, covering all categories of COPD inhalation therapy drugs, proving that the domestic market in this field is also rapidly rising, and the development prospects are very broad.
HealthGen will continue to take innovation and R&D as its core to drive the group's development, "putting the people's lives and health first," bringing high-quality inhalation preparations to Chinese respiratory disease patients. To benefit China's chronic airway disease patients and contribute to Healthy China 2030!
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.